MetaCap

Ardelyx (ARDX) vs Collegium Pharmaceutical (COLL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ardelyx (ARDX) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 44.8% versus a loss of 45.2%. Over five years, ARDX leads with a +234.8% price change compared with +37.7% for COLL. Collegium Pharmaceutical is the larger company by market cap ($768.2 million vs $751.6 million), about 1.0 times the size.

On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.5x vs 18.9x for Ardelyx). Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus -15.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARDX-44.83%COLL-45.24%
+52%-2%-57%
Nov 21, 20251 yearNov 20, 2026
ARDX+199.00%COLL+31.14%
+920%+415%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARDX versus COLL key metrics
MetricARDXCOLL
Share price$2.99$24.72
Market cap$751.60M$768.18M
1-day change-2.29%-1.94%
YTD return-48.71%-46.61%
1-year return-44.83%-45.24%
5-year return+234.83%+37.72%
P/E ratio (TTM)—22.68
Forward P/E18.923.49
EPS (TTM)$-0.23$1.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$407.32M$780.57M
Revenue growth (YoY)+22.09%+23.62%
Net income (latest FY)$-61.60M$62.87M
Gross margin90.29%59.35%
Operating margin-10.06%23.01%
Net margin-15.12%8.05%
52-week high$8.40$50.79
52-week low$2.80$21.43
Distance from 52-week high-64.40%-51.33%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+318.06%+77.99%
Average volume4.46M754.45K
Shares outstanding251.37M31.08M
Employees489423
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -15.1 cents for Ardelyx.

About Ardelyx

ARDX stock →

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees

About Collegium Pharmaceutical

COLL stock →

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees

ARDX vs COLL FAQ

Which is bigger, Ardelyx or Collegium Pharmaceutical?

Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $768.18M compared with $751.60M for Ardelyx (ARDX).

Which stock has performed better over the past year, ARDX or COLL?

ARDX returned -44.83% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.

Are Ardelyx and Collegium Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons